| 1 | 11206271 | Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. | J Cancer Res Clin Oncol | 2001 Jan |
2 |
| 2 | 11410411 | In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. | Haematologica | 2001 May |
1 |
| 3 | 12029443 | Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines. | J Cancer Res Clin Oncol | 2002 May |
1 |
| 4 | 12756557 | Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer. | J Cancer Res Clin Oncol | 2003 May |
2 |
| 5 | 12948851 | Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. | Biochem Pharmacol | 2003 Sep 1 |
9 |
| 6 | 15621757 | Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. | Leuk Lymphoma | 2004 Dec |
2 |
| 7 | 16088404 | Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). | J Cancer Res Clin Oncol | 2006 Feb |
1 |
| 8 | 17414628 | A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors. | Anticancer Drugs | 2007 Jun |
1 |
| 9 | 17653574 | Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways. | J Cancer Res Clin Oncol | 2008 Feb |
13 |
| 10 | 18716777 | Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial. | Cancer Chemother Pharmacol | 2009 Apr |
1 |
| 11 | 18980985 | Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. | Clin Cancer Res | 2008 Nov 1 |
3 |
| 12 | 19263299 | Bendamustine-containing immunochemotherapy is active in transformed follicular lymphoma with overexpression of p53. | Leuk Lymphoma | 2009 Mar |
1 |
| 13 | 21257672 | Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. | Ann Oncol | 2011 Aug |
1 |
| 14 | 21454214 | Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia. | Clin Lymphoma Myeloma Leuk | 2011 Feb |
1 |
| 15 | 21530768 | Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity. | Semin Hematol | 2011 Apr |
1 |
| 16 | 21624007 | Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. | Cancer Sci | 2011 Sep |
1 |
| 17 | 22347385 | Neovascular niche for human myeloma cells in immunodeficient mouse bone. | PLoS One | 2012 |
1 |
| 18 | 22624727 | Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo. | Br J Pharmacol | 2012 Oct |
1 |
| 19 | 22653969 | The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells. | Mol Cancer Ther | 2012 Aug |
2 |
| 20 | 23380051 | Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. | Cell Signal | 2013 May |
5 |
| 21 | 23390564 | Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells. | Am J Transl Res | 2013 |
12 |
| 22 | 23430121 | Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. | Cancer Chemother Pharmacol | 2013 May |
1 |
| 23 | 23450436 | The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia. | Am J Hematol | 2013 Apr |
1 |
| 24 | 23459296 | Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response. | Cancer Lett | 2013 Jul 28 |
4 |
| 25 | 23688587 | Everolimus enhances the cytotoxicity of bendamustine in multiple myeloma cells through a network of pro-apoptotic and cell-cycle-progression regulatory proteins. | Acta Biochim Biophys Sin (Shanghai) | 2013 Aug |
1 |
| 26 | 23692564 | Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077. | Br J Haematol | 2013 Jul |
1 |
| 27 | 23986050 | [Bendamustine-rituximab therapy is effective for transformed follicular lymphoma with significant expression of p53]. | Gan To Kagaku Ryoho | 2013 Aug |
2 |
| 28 | 24111951 | Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis. | Br J Haematol | 2014 Jan |
1 |
| 29 | 24308434 | Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other. | Leuk Lymphoma | 2014 Sep |
1 |
| 30 | 24344029 | Proteomic studies of multiple myeloma in RPMI8226 cell line treated with bendamustine. | J BUON | 2013 Oct-Dec |
2 |
| 31 | 24398467 | Competitive interactions of anti-carcinogens with serum albumin: a spectroscopic study of bendamustine and dexamethasone with the aid of chemometrics. | Spectrochim Acta A Mol Biomol Spectrosc | 2014 Apr 5 |
3 |
| 32 | 24626203 | Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies. | PLoS One | 2014 |
1 |
| 33 | 24681707 | Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia. | Oncotarget | 2014 Mar 15 |
1 |
| 34 | 24912431 | The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia. | Leukemia | 2015 Jan |
1 |
| 35 | 24951124 | Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab. | Ann Hematol | 2014 Nov |
1 |
| 36 | 25133896 | Bortezomib/bendamustine/dexamethasone induced good PR in refractory relapse post auto-SCT with constitutive RAS activation due to V600E BRAF mutation. | Bone Marrow Transplant | 2014 Dec |
1 |
| 37 | 25477469 | Renal human organic anion transporter 3 increases the susceptibility of lymphoma cells to bendamustine uptake. | Am J Physiol Renal Physiol | 2015 Feb 15 |
6 |
| 38 | 25481222 | Interaction of human organic anion transporter 2 (OAT2) and sodium taurocholate cotransporting polypeptide (NTCP) with antineoplastic drugs. | Pharmacol Res | 2015 Jan |
8 |
| 39 | 25582574 | Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells. | Pharmacogenomics J | 2015 Aug |
7 |
| 40 | 25663907 | Prognostic role of translocator protein and oxidative stress markers in chronic lymphocytic leukemia patients treated with bendamustine plus rituximab. | Oncol Lett | 2015 Mar |
2 |
| 41 | 25705531 | Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan. | Case Rep Neurol Med | 2015 |
2 |
| 42 | 25829094 | Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. | Cancer Chemother Pharmacol | 2015 Jun |
2 |
| 43 | 25833722 | Increased number of peripheral CD8+ T cells but not eosinophils is associated with late-onset skin reactions caused by bendamustine. | Int J Hematol | 2015 Jul |
2 |
| 44 | 25975443 | Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation. | Curr Treat Options Oncol | 2015 Jun |
3 |
| 45 | 26196503 | Esters of Bendamustine Are by Far More Potent Cytotoxic Agents than the Parent Compound against Human Sarcoma and Carcinoma Cells. | PLoS One | 2015 |
1 |
| 46 | 26581069 | New patterns of relapse in multiple myeloma: a case of "light chain escape" in which FLC predicted relapse earlier than urine and serum immunofixation. | Clin Chem Lab Med | 2016 Jun 1 |
1 |
| 47 | 26701728 | CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia. | Oncotarget | 2016 Feb 2 |
9 |
| 48 | 27103007 | Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study. | Ann Hematol | 2016 Jun |
2 |
| 49 | 27120083 | Infusion Rate Dependent Pharmacokinetics of Bendamustine with Altered Formation of γ-hydroxybendamustine (M3) Metabolite Following 30- and 60-min Infusion of Bendamustine in Rats. | Drug Res (Stuttg) | 2016 Jul |
2 |
| 50 | 27245314 | Anti Myelin-Associated-Glycoprotein Antibody Peripheral Neuropathy Response to Combination Chemoimmunotherapy With Bendamustine/Rituximab in a Patient With Biclonal IgM κ and IgM λ: Case Report and Review of the Literature. | Clin Lymphoma Myeloma Leuk | 2016 Jul |
1 |